Search
Kiniksa Pharmaceuticals International PLC
KNSAAdd to Watchlist
93.860USD
+5.520+6.25%
Close 11-06 16:00（ET）
7.37BMarket Cap
96.37P/E TTM
After-hours 17:36 (ET)94.440USD+0.550+0.59%
After-hours 17:36 (ET)Today
+6.25%
5 Days
+1.76%
1 Month
+21.75%
6 Months
+61.19%
Year to Date
+127.54%
1 Year
+142.97%
Key Figures
88.920Open
94.480High
37.28KVolume
96.37P/E TTM
46.63P/E Dynamic
--Dividend TTM
0.05%Turnover Ratio
88.340Prev. Close
88.409Low
3.45MTurnover
LossP/E Static
10.37P/B
0.00%Div Yield TTM
10.26%ROA
98.48052wk High
0.04Volume Ratio
-43.19MNet Profit
78.57MShares
0.9729EPS TTM
0.14Beta
13.74%ROE
37.02052wk Low
10.97%Amplitude
90.30%Gross Margin
7.37BMarket Cap
9.20Reward/Risk
3.54%Risk Rate
Recent
Transcripts
More news coming soon, stay tuned...
Kiniksa Pharmaceuticals International PLC's Score
0.00vs previous score
Forecast8.75
Financial Health8.41
Technical5.33
Valuation Dimensions7.10
Institutional Confidence10.00
Risk Assessment6.60
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
Kiniksa Pharmaceuticals International PLC Technical Analysis
Technical Indicators
Buy
Summary
Buy
Moving Average
Strong buy
Kiniksa Pharmaceuticals International PLC Latest Earnings Call Transcripts
Kiniksa Pharmaceuticals (KNSA) Q3 2026 Earnings Call: ARCALYST Guidance Raised
Kiniksa Pharmaceuticals’ Q3 2026 earnings call covered 58% ARCALYST growth, raised 2026 sales guidance and the KPL-387 Phase III timeline.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
0.61/0.37
Revenue / Forecast
285.97M/260.61M
Kiniksa Pharmaceuticals International PLC Profile
SectorPharmaceuticals
Ticker SymbolKNSA
Number of employees315
CountryUnited Kingdom
Ownership
| Shareholders | Proportion |
|---|---|
| Fidelity Management & Research Company LLC | 10.48% |
| Rubric Capital Management LP | 7.19% |
| Baker Bros. Advisors LP | 6.10% |
| Tang Capital Management, LLC | 4.88% |
| Shareholder Types | Proportion |
|---|---|
| Hedge Fund | 37.95% |
| Investment Advisor | 30.61% |
| Investment Advisor/Hedge Fund | 27.20% |
| Research Firm | 6.68% |
Related Instruments
-0.79%
+1.43%
+1.07%
-0.14%
+0.38%
-0.22%
+0.03%
-0.41%
+0.02%
-0.20%
+0.85%
-1.57%
-1.04%
+0.28%
+5.27%
-0.16%
+0.16%
-0.80%
+1.46%
+3.63%Popular Instruments
51290.600
-208.500 (-0.41%)
26964.500
+329.300 (+1.24%)
7380.000
+23.100 (+0.31%)
12797.000
-1.000 (-0.01%)
58142.000
+876.000 (+1.53%)
6140.600
-37.200 (-0.60%)
89.857
-0.176 (-0.20%)
342.370
-1.800 (-0.52%)
186.640
+5.040 (+2.78%)
4065.670
-33.020 (-0.81%)
FAQs
What is the current price of Kiniksa Pharmaceuticals International PLC (KNSA)?
The current price of Kiniksa Pharmaceuticals International PLC (KNSA) is 93.86.
What is the symbol of Kiniksa Pharmaceuticals International PLC?
The ticker symbol of Kiniksa Pharmaceuticals International PLC is KNSA.
What is the 52-week high of Kiniksa Pharmaceuticals International PLC?
The 52-week high of Kiniksa Pharmaceuticals International PLC is 98.48.
What is the 52-week low of Kiniksa Pharmaceuticals International PLC?
The 52-week low of Kiniksa Pharmaceuticals International PLC is 37.02.
What is the market capitalization of Kiniksa Pharmaceuticals International PLC?
The market capitalization of Kiniksa Pharmaceuticals International PLC is 7.37B.
Is Kiniksa Pharmaceuticals International PLC (KNSA) currently rated as Buy, Hold, or Sell?
According to analysts, Kiniksa Pharmaceuticals International PLC (KNSA) has an overall rating of Buy, with a price target of 109.43.
What is the Earnings Per Share (EPS TTM) of Kiniksa Pharmaceuticals International PLC (KNSA)?
The Earnings Per Share (EPS TTM) of Kiniksa Pharmaceuticals International PLC (KNSA) is 0.97.